Patent ID: 11155830

Abstract:
The present invention discloses preparation and use of a nanoparticle-doped RNA hydrogel targeting to a triple negative breast cancer (TNBC). The RNA hydrogel is a pure RNA system formed in a rolling circle transcription manner. The transcription process generates a large number of GC bonds, which provides a large number of sites for the introduction of DOX. The large number of RNA copy structures generated by rolling circle replication is a polyanionic aggregate. Due to the strong electronegativity of the polyanionic aggregate, electropositive MnO2@Ce6 nanoparticles are introduced, such that the colloid cationic MnO2@Ce6 particles can be stabilized by the polyanionic hydrogel, and thus target into a breast cancer cell for synergistic treatment. It can be used for a drug slow release system, has good biocompatibility, and has broad prospects in the fields of growth inhibition effects on targeted MDA-MB-231 tumor cells, inhibition of cancer metastasis and recurrence, and the like.